ADHD Medications Across the Lifespan: A PMHNP Exam Review

On the PMHNP board exam, the highest-yield ADHD facts are that stimulants (methylphenidate and amphetamine classes) are first-line, that they work by increasing synaptic dopamine and norepinephrine, and that they require cardiovascular screening before starting plus growth and blood-pressure monitoring during treatment. Non-stimulants — atomoxetine, viloxazine, and the alpha-2 agonists guanfacine and clonidine — are the key second-line options to know cold.

This review organizes ADHD pharmacology the way the exam tests it: mechanism, adverse effects, monitoring, controlled-substance handling, and lifespan-specific nuances.

Stimulants: The First-Line Workhorses

Stimulants are the most effective ADHD treatments and the default starting point for most patients across the lifespan. They divide into two chemical families.

Methylphenidate class

Methylphenidate (and dexmethylphenidate) primarily blocks reuptake of dopamine and norepinephrine by inhibiting the dopamine and norepinephrine transporters. Common brand formulations include immediate-release tablets and long-acting delivery systems. For the exam, associate methylphenidate with a slightly gentler side-effect profile and frequent use as a starting agent in children.

Amphetamine class

Amphetamines (mixed amphetamine salts, lisdexamfetamine, dextroamphetamine) do more than block reuptake — they also promote release of dopamine and norepinephrine from presynaptic vesicles and weakly inhibit monoamine oxidase. Lisdexamfetamine is a prodrug, cleaved to active dextroamphetamine in the bloodstream, which gives it a smoother onset and lower abuse appeal.

Key exam contrast: methylphenidate mainly blocks reuptake; amphetamines block reuptake and trigger release.

Stimulant adverse effects

• Appetite suppression and weight loss — the most common reason to monitor growth in children.
• Insomnia — dose timing matters; avoid late-day dosing.
• Increased heart rate and blood pressure.
• Headache, irritability, and emotional lability, sometimes worst as the dose wears off (rebound).
• Tics may emerge or worsen, though stimulants are not absolutely contraindicated with tic disorders.
• Psychosis or mania can be precipitated, especially at high doses or in vulnerable patients.

Non-Stimulants: Second-Line and Specialty Options

Non-stimulants are chosen when stimulants fail, are poorly tolerated, are contraindicated, or when there is concern about diversion or substance use.

Atomoxetine

Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI). It is not a controlled substance, has no abuse potential, and takes several weeks to reach full effect. Counsel patients that benefit is delayed compared with stimulants.

• Adverse effects: GI upset, decreased appetite, sedation or insomnia, and sexual dysfunction in adults.
• It carries a boxed warning for suicidal ideation in children and adolescents.
• Use caution with hepatotoxicity and with CYP2D6 poor metabolizers, who reach higher levels.

Viloxazine

Viloxazine is a newer extended-release norepinephrine reuptake inhibitor with serotonergic activity, approved for children, adolescents, and adults. Like atomoxetine, it is non-controlled and also carries a suicidality boxed warning. Watch for somnolence, decreased appetite, and blood-pressure or heart-rate changes.

Alpha-2 agonists: guanfacine and clonidine

Extended-release guanfacine and clonidine are central alpha-2 adrenergic agonists. They reduce sympathetic outflow and are useful for hyperactivity, impulsivity, sleep problems, and as adjuncts to stimulants.

• Sedation and hypotension are the hallmark effects — guanfacine is more selective and less sedating than clonidine.
• Do not stop abruptly: sudden discontinuation can cause rebound hypertension. Taper instead.
• Monitor blood pressure and heart rate; bradycardia is possible.

Cardiac and Growth Monitoring

Monitoring questions are reliably tested. Build your answer around this framework.

Before starting a stimulant:

• Take a thorough cardiac history (syncope, palpitations, exertional symptoms) and family history (sudden cardiac death, known structural heart disease).
• Examine and check baseline heart rate and blood pressure.
• A routine ECG is not required for asymptomatic patients with a normal history and exam. Order one when the history, family history, or exam suggests cardiac disease.

During treatment:

• Recheck blood pressure and heart rate at follow-up visits.
• Track height and weight on growth charts in children; persistent appetite suppression can blunt growth velocity.
• Reassess sleep, mood, and any tics.

Stimulants are generally avoided in patients with serious structural cardiac abnormalities, symptomatic cardiovascular disease, or uncontrolled hypertension. They are also contraindicated within 14 days of an MAOI because of hypertensive-crisis risk.

Controlled-Substance Considerations

Stimulants are Schedule II controlled substances. The PMHNP exam expects you to know the prescribing and stewardship implications.

• Schedule II prescriptions generally cannot be refilled; a new prescription is required each fill (though multiple sequential prescriptions may be issued where state law allows).
• Screen for diversion and misuse, particularly in adolescents and college-age adults; prodrug lisdexamfetamine and long-acting formulations carry lower abuse liability.
• Check the prescription drug monitoring program (PDMP) per state requirements.
• For patients with active substance use disorder, favor non-stimulants such as atomoxetine, viloxazine, or alpha-2 agonists. See our overview of medication-assisted treatment for managing comorbid SUD.

Lifespan Nuances

Children and adolescents

• Stimulants are first-line; behavioral therapy is combined, and for preschoolers behavioral intervention is emphasized first.
• Watch growth and appetite closely.
• Atomoxetine and viloxazine both carry suicidality boxed warnings in this age group — counsel families and monitor mood.
• A diagnosis still requires symptoms present before age 12 and across more than one setting per DSM-5-TR.

Adults

• ADHD persists into adulthood for many patients; symptoms shift toward inattention, disorganization, and emotional dysregulation.
• Confirm childhood-onset symptoms and screen for comorbid anxiety, depression, and substance use.
• Cardiovascular screening matters more because acquired heart disease and hypertension are more common.

Geriatric patients

• Use stimulants cautiously; older adults have higher cardiovascular risk and sensitivity to blood-pressure and heart-rate effects.
• Start low and titrate slowly; reassess cognition, falls risk, and sleep.
• Alpha-2 agonists raise concern for hypotension and bradycardia in this group.

Exam reminder: This article is for board preparation only. Always verify dosing, contraindications, and monitoring against current FDA prescribing information and clinical guidelines before treating a patient.

Pulling It Together for the Exam

When a vignette describes a child with classic ADHD and no cardiac red flags, the answer is usually a stimulant with growth and vital-sign monitoring. When the stem adds substance-use risk, diversion concern, tics, or stimulant intolerance, pivot to a non-stimulant. When you see do not stop abruptly and rebound hypertension, think alpha-2 agonist. And whenever atomoxetine or viloxazine appears in a pediatric stem, remember the suicidality boxed warning.

For more cross-cutting safety content, review our guide to black box warnings every PMHNP must memorize and the broader PMHNP psychopharmacology high-yield review.

Ready to test these concepts under exam conditions? Take a free diagnostic assessment to find your weak spots, then drill verified PMHNP questions at PASSNP. Create your free account to start practicing today.